

## Supporting Information

*J. Chem. Metrol.* 16:2 (2022) 111-124


### Validated chromatographic methods for concurrent determination of atorvastatin and perindopril

Sagar Patel, Chandani Patel Jasmina Surati, Ashok Akabari


and Ketan Shah

*Shree Naranjibhai Lalbhai Patel College of Pharmacy, Umrakh, Gujarat, India*


Table of Content	Page No.
<b>Figure S1:</b> IR spectra of atorvastatin	2
<b>Figure S2:</b> IR spectra of perindopril	2
<b>Figure S3.</b> Photograph of calibration curve of ato (800-4800ng/band), per (200-1200 ng/band)	3
<b>Figure S4:</b> Blank chromatogram of mobile phase	3
<b>Figure S5:</b> Densitogram of atorvastatin (2400ng/band), perindopril (600ng/band) using dichloromethane: methanol: ethyl acetate: glacial acetic acid (6:2:2:0.1, v/v/v/v) as a mobile phase	4
<b>Figure S6:</b> Chromatogram of ATO (40 $\mu$ g/mL) and PER (10 $\mu$ g/mL) in acetonitrile: methanol: buffer (40:10:50v/v/v) (ph 3) having RT of ATO at 4.39 min and PER at 7.82 min	4
<b>Figure S7:</b> Peak purity spectra of calibration range	5
<b>Figure S8:</b> Chromatogram of ATO (10 $\mu$ g/mL) in acetonitrile: methanol: Buffer (40:10:50v/v/v) (pH 3)	5
<b>Figure S9:</b> Chromatogram of PER (10 $\mu$ g/mL) in acetonitrile: methanol: buffer (40:10:50v/v/v) (pH 3)	6
<b>Figure S10:</b> Chromatogram of mobile phase	6
<b>Table S1:</b> Linearity of atorvastatin and perindopril (HPTLC method)	7
<b>Table S2:</b> Result of intermediate precision of atorvastatin (HPTLC method)	7
<b>Table S3:</b> Result of intermediate precision of perindopril (HPTLC method)	7
<b>Table S4:</b> Result of repeatability precision of atorvastatin (HPTLC method)	8
<b>Table S5:</b> Result of repeatability precision of perindopril (HPTLC method)	8
<b>Table S6:</b> Accuracy data of atorvastatin (HPTLC method)	8
<b>Table S7:</b> Accuracy data of perindopril (HPTLC method)	8
<b>Table S8:</b> Assay result of synthetic mixture (HPTLC method)	9
<b>Table S9:</b> Linearity of atorvastatin and perindopril (HPLC method)	9
<b>Table S10:</b> Intraday precision data for estimation of ATO and PER (n=3) (HPLC method)	9
<b>Table S11:</b> Interday precision data for estimation of ATO and PER (n=3) (HPLC method)	9
<b>Table S12:</b> Repeatability data for ATO and PER (HPLC method)	10
<b>Table S13:</b> Accuracy data of ATO (HPLC method)	10
<b>Table S14:</b> Accuracy data of PER (HPLC method)	10
<b>Table S15:</b> Analysis data of formulation (HPLC method)	11
<b>Table S16:</b> F-Test two-sample for variances	11




**Figure S1:** IR Spectra of atorvastatin




**Figure S2:** IR Spectra of perindopril




**Figure S3:** Photograph of calibration curve of ATO A1-A6 (800-4800ng/band), PER P1-P6 (200-1200 ng/band)




**Figure S4:** Blank chromatogram of mobile phase




**Figure S5:** Densitogram of atorvastatin (2400ng/band), perindopril (600ng/band) using dichloromethane: methanol: ethyl acetate: glacial acetic acid (6:2:2:0.1, v/v/v/v) as a mobile phase




**Figure S6:** Chromatogram of ATO (40 $\mu$ g/mL) and PER (10 $\mu$ g/mL) in acetonitrile: methanol: buffer (40:10:50v/v/v) (ph 3) having RT of ATO at 4.39 min and PER at 7.82 min




**Figure S7:** Peak purity spectra of calibration range



**Figure S8:** Chromatogram of ATO (10 $\mu$ g/ml) in Acetonitrile: Methanol: Buffer(40:10:50v/v/v) (pH 3)



**Figure S9:** Chromatogram of PER (10 $\mu$ g/ml) in Acetonitrile: Methanol: Buffer(40:10:50v/v/v) (pH 3)



**Figure S10:** Chromatogram of mobile phase

**Table S1:** Linearity of atorvastatin and perindopril (HPTLC method)

Sr. no	Concentration (ng/band)	Perindopril		Atorvastatin	
		Mean peak area ± S.D. (n=6)	R.S.D. (%)	Mean peak area ± S.D. (n=6)	R.S.D. (%)
1	800	5899.2 ± 86.78	1.84	630.01 ± 9.98	1.73
2	1600	10432.7 ± 108.21	1.71	1368.21 ± 3.86	0.28
3	2400	15821.5 ± 89.62	0.57	2310.01 ± 21.90	0.95
4	3200	19978.7 ± 140.29	0.78	3038.63 ± 57.62	1.85
5	4000	24987.2 ± 155.84	1.13	4138.1 ± 51.42	1.23
6	4800	29958.2 ± 202.80	1.02	5002.35 ± 58.36	1.12

**Table S2:** Result of intermediate precision of atorvastatin (HPTLC method)

Atorvastatin Conc.(ng/band)	Intraday		Interday	
	Area ± SD (n=3)	%RSD	Area ± SD (n=3)	%RSD
800	5770.86 ± 91.62	1.58	5781.7 ± 92.42	1.21
2400	15847.83 ± 72.19	0.45	15645.43 ± 69.78	0.68
4800	30079.17 ± 423.27	1.40	30125.17 ± 356.04	1.24

**Table S3:** Result of intermediate precision of perindopril (HPTLC method)

Perindopril Conc. (ng/band)	Intraday		Interday	
	Area ± SD (n=3)	%RSD	Area ± SD (n=3)	%RSD
200	635.83 ± 4.64	0.73	629.13 ± 3.96	0.98
600	3073.03 ± 41.40	1.34	3056.41 ± 31.40	1.24
1200	5051.13 ± 31.77	0.62	5123.4 ± 29.76	1.65

**Table S4:** Result of repeatability precision of atorvastatin (HPTLC method)

Injection		Rf value		
Conc.ng/band	Area ± SD (n=6)	%RSD	Rf ± SD (n=6)	%RSD
2400	11055.65±162.95	1.47	0.70 ± 0.0037	0.52

**Table S5:** Result of repeatability precision of perindopril (HPTLC method)

Injection		Rf value		
Conc.ng/band	Area ± SD(n=6)	%RSD	Rf ± SD (n=6)	%RSD
600	1414.55 ± 27.04	1.91	0.39 ± 0.0035	0.95

**Table S6:** Accuracy data of atorvastatin (HPTLC method)

Level	Conc. of ATO from Synthetic mixture (µg/ml)	Amount of Std. ATO added (µg/ml)	Total amount of ATO (µg/ml)	Total amount of ATO Recovered (µg/ml) * Mean ± SD	% Recovery	% RSD
50%	1600	800	2400	2428.4±84.47	101.18%	0.028
100%	1600	1600	3200	32183.9±415.3	100.59%	1.97
150%	1600	2400	4000	2607.9±983.33	100.65%	1.58

**Table S7:** Accuracy data of perindopril (HPTLC method)

Level	Conc. of PER from Synthetic mixture (µg/ml)	Amount of Std. PER added (µg/ml)	Total amount of PER (µg/ml)	Total amount of PER Recovered (µg/ml) Mean ± SD	% Recovery	% RSD
50%	400	200	600	605.34±9.52	99.79%	0.41
100%	400	400	800	801.27±272.28	100.54%	1.21
150%	400	600	1000	1011±7.37	101.1%	0.98

**Table S8:** Assay result of synthetic mixture (HPTLC method)

<b>Formulation</b>	<b>Drug</b>	<b>Conc.</b> <b>(ng/band)</b>	<b>%Assay± SD</b> <b>(n=3)</b>	<b>% R.S.D</b>
Synthetic mixture	Atorvastatin	2400	101.6±30.15	1.21
	Perindopril	600	100.42 ± 45.34	1.76

**Table S9:** Linearity of Atorvastatin and Perindopril (HPLC method)

<b>Sr. no</b>	<b>Concentration (<math>\mu\text{g/ml}</math>)</b>	<b>Perindopril</b>		<b>Atorvastatin</b>	
		<b>Mean peak area ± S.D. (n=6)</b>	<b>R.S.D. (%)</b>	<b>Mean peak area ± S.D. (n=6)</b>	<b>R.S.D. (%)</b>
1	10	5985±105.32	1.73	14986±289.98	1.90
2	20	12452±225.30	1.83	31246±328.88	1.05
3	30	17895±314.26	1.73	45095±351.54	0.76
4	40	24423±202.85	0.84	61562±390.03	0.63
5	50	29895±194.57	0.64	75426±400.45	0.52

**Table S10:** Intraday precision data for estimation of ATO and PER (n=3) (HPLC method)

<b>Conc. (<math>\mu\text{g/ml}</math>)</b>		<b>Mean peak area</b>	<b>% RSD</b>	<b>Mean peak area</b>	<b>% RSD</b>
<b>ATO</b>	<b>PER</b>	<b>±SD</b>		<b>±SD</b>	
		<b>ATO</b>		<b>PER</b>	
20	10	15063±269.22	1.78	6109.33±88.46	1.44
60	30	45076±98.04	0.21	18002.67±228.55	1.26
100	50	76025.33±136.10	0.17	28031.33±308.03	1.09

**Table S11:** Interday precision data for estimation of ATO and PER (n=3) (HPLC method)

<b>Conc. (<math>\mu\text{g/ml}</math>)</b>		<b>Mean peak area</b>	<b>% RSD</b>	<b>Mean peak area ± SD</b>	<b>% RSD</b>
<b>ATO</b>	<b>PER</b>	<b>±SD</b>		<b>±SD</b>	
		<b>ATO</b>		<b>PER</b>	
20	10	15213±207.88	1.36	5929.33±14.07	0.23
60	30	45348.33±303.93	0.67	18017.33±221.69	1.23
100	50	176350±339.04	0.44	29246.67±236.51	0.80

**Table S12:** Repeatability data for ATO and PER (HPLC method)

Drug	Concentration ( $\mu\text{g/ml}$ )	Mean peak area $\pm$	% R.S.D.
		S.D. (n=7)	
ATO	40	31837.83 $\pm$ 327.53	1.02
PER	20	12671.33 $\pm$ 252.68	1.99

**Table S13:** Accuracy data of ATO (HPLC method)

Level	Conc. of	Amount of	Total amount	Total amount	%	%
	ATO from	Std. ATO	of ATO	of ATO	Recovery	RSD
	Synthetic	added	( $\mu\text{g/ml}$ )	Recovered		
	mixture	( $\mu\text{g/ml}$ )		( $\mu\text{g/ml}$ ) *		
		( $\mu\text{g/ml}$ )		Mean $\pm$ SD		
50%	40	20	60	59.38 $\pm$ 399.24	98.96%	0.87
100%	40	40	80	80.43 $\pm$ 143.77	100.53%	0.23
150%	40	60	100	99.33 $\pm$ 266.37	99.33%	0.35

**Table S14:** Accuracy data of PER (HPLC method)

Level	Conc. of	Amount of	Total	Total amount	%	%
	PER from	Std. PER	amount of	of PER	Recovery	RSD
	Synthetic	added	PER	Recovered		
	Mixture	( $\mu\text{g/ml}$ )	( $\mu\text{g/ml}$ )	( $\mu\text{g/ml}$ )		
	( $\mu\text{g/ml}$ )			Mean $\pm$ SD		
50%	10	5	15	15.07 $\pm$ 25.31	100.52%	0.27
100%	10	10	20	20.59 $\pm$ 61.75	100.95%	0.49
150%	10	15	25	237.36 $\pm$ 25.08	100.33%	1.56

**Table S15:** Analysis data of formulation (HPLC method)

Sr. No	Drug	Concentration ( $\mu\text{g}/\text{ml}$ )	% Assay $\pm$ SD	%R.S. D
1	ATO	40	100.98 $\pm$ 200.31	0.60
2	PER	10	100.00 $\pm$ 60.53	0.46

**Table S16:** F-test two-sample for variances

	Perindopril		Atorvastatin	
	HPLC	HPTLC	HPLC	HPTLC
<b>Mean</b>	100.446	100.15	100.12	100.3
<b>Variance</b>	0.18628	0.10885	0.467	0.425
<b>Observations</b>	5	5	5	5
<b>df</b>	4	4	4	4
<b>F</b>	1.711345889		1.098824	
<b>P(F<math>\leq</math>f) one-tail</b>	0.307745467		0.464712	
<b>F Critical one-tail</b>	6.388232909		6.388233	